Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART

Kanters, Steve; Karim, Mohammad Ehsanul; Thorlund, Kristian; Anis, Aslam H.; Zoratti, Michael; Bansback, Nick

doi:10.1186/s12874-021-01254-5

Table 2 Comparison of comparative treatment estimates of all models considered in the analysis for viral suppression at 48 weeks as an outcome

From: Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART

Analyses	Model	DTG vs. EFV OR (95% CrI)	EFV₄₀₀ vs. EFV OR (95% CrI)	DTG vs. EFV₄₀₀ OR (95% CrI)	Mean change in log-odds	Maximum change in log-odds	Mean change in proportion	Maximum change in proportion
AgD NMA – Unadjusted	Fixed	1.85 (1.44, 2.38)	1.15 (0.75, 1.80)	1.61 (0.96, 2.68)	–	–	–	–
AgD NMA meta-regression – CD4	Fixed	1.87 (1.49, 2.39)	1.16 (0.74, 1.97)	1.62 (0.92, 2.59)	0.033	0.089	0.005	0.015
AgD NMA meta-regression – HIV RNA	Fixed	1.85 (1.45, 2.38)	1.15 (0.75, 1.80)	1.61 (0.97, 2.67)	0.001	0.004	0	0
AgD NMA meta-regression – Male	Fixed	1.85 (1.45, 2.38)	1.17 (0.73, 1.86)	1.59 (0.93, 2.73)	0.003	0.013	0	0.002
Two-stage AgD NMA – CD4 + HIV RNA + Male	Fixed	1.44 (1.12, 1.85)	1.16 (0.75, 1.80)	1.24 (0.75, 2.05)	0.063	0.266	0.01	0.042
Two-stage AgD NMA – CD4 + Male	Fixed	1.50 (1.16, 1.93)	1.15 (0.74, 1.81)	1.30 (0.78, 2.16)	0.057	0.221	0.01	0.035
Two-stage AgD NMA – CD4 + HIV RNA	Fixed	1.59 (1.23, 2.04)	1.16 (0.74, 1.80)	1.37 (0.82, 2.28)	0.056	0.183	0.009	0.029
Two-stage AgD NMA – HIV RNA + Male	Fixed	1.49 (1.16, 1.93)	1.15 (0.74, 1.79)	1.29 (0.78, 2.15)	0.065	0.238	0.009	0.036
Two-stage AgD NMA – HIV RNA	Fixed	1.34 (1.04, 1.74)	1.16 (0.74, 1.80)	1.16 (0.70, 1.94)	0.073	0.32	0.012	0.052
Two-stage AgD NMA – CD4	Fixed	1.46 (1.12, 1.91)	1.15 (0.75, 1.79)	1.27 (0.75, 2.11)	0.072	0.253	0.011	0.04
Two-stage AgD NMA – Male	Random	1.44 (1.05, 1.99)	1.15 (0.66, 2.04)	1.24 (0.65, 2.39)	0.059	0.299	0.008	0.044
One-stage IPD-AgD NMA – unadjusted	Fixed	1.60 (1.26, 2.02)	1.16 (0.75, 1.80)	1.38 (0.84, 2.27)	0.046	0.155	0.014	0.03
One-stage IPD-AgD NMA – CD4 + HIV RNA+ Male	Fixed	1.57 (1.23, 2.00)	1.10 (0.70, 1.72)	1.43 (0.86, 2.38)	0.076	0.167	0.052	0.068
One-stage IPD-AgD NMA – CD4 + Male	Fixed	1.54 (1.21, 1.95)	1.12 (0.72, 1.75)	1.37 (0.83, 2.26)	0.085	0.187	0.031	0.05
One-stage IPD-AgD NMA – CD4 + HIV RNA	Fixed	1.57 (1.24, 2.00)	1.10 (0.70, 1.72)	1.43 (0.85, 2.39)	0.076	0.166	0.03	0.048
One-stage IPD-AgD NMA – HIV RNA + Male	Fixed	1.58 (1.24, 2.01)	1.11 (0.71, 1.73)	1.41 (0.85, 2.36)	0.06	0.161	0.054	0.07
One-stage IPD-AgD NMA – CD4	Fixed	1.54 (1.22, 1.95)	1.12 (0.72, 1.75)	1.38 (0.84, 2.26)	0.083	0.181	0.02	0.037
One-stage IPD-AgD NMA – HIV RNA	Fixed	1.56 (1.23, 1.97)	1.12 (0.72, 1.75)	1.39 (0.85, 2.27)	0.066	0.174	0.022	0.039
One-stage IPD-AgD NMA – Male	Fixed	1.61 (1.27, 2.04)	1.15 (0.74, 1.80)	1.39 (0.83, 2.33)	0.042	0.142	0.008	0.026
Two-stage empirical-priors – CD4 + HIV RNA + Male	Fixed	1.60 (1.21, 2.13)	1.08 (0.68, 1.70)	1.48 (0.87, 2.54)	0.102	0.271	0.022	0.049
Two-stage empirical-priors – CD4 + Male	Fixed	1.62 (1.24, 2.12)	1.10 (0.70, 1.71)	1.48 (0.88, 2.49)	0.106	0.245	0.023	0.047
Two-stage empirical-priors – CD4 + HIV RNA	Fixed	1.65 (1.25, 2.17)	1.09 (0.70, 1.71)	1.50 (0.88, 2.54)	0.087	0.233	0.016	0.042
Two-stage empirical-priors – HIV RNA + Male	Fixed	1.58 (1.21, 2.05)	1.10 (0.70, 1.74)	1.43 (0.85, 2.40)	0.092	0.194	0.02	0.039
Two-stage empirical-priors – CD4	Fixed	1.67 (1.28, 2.17)	1.11 (0.71, 1.73)	1.50 (0.90, 2.52)	0.092	0.211	0.019	0.041
Two-stage empirical-priors – HIV RNA	Fixed	1.58 (1.24, 2.03)	1.11 (0.71, 1.74)	1.42 (0.85, 2.37)	0.083	0.178	0.021	0.04
Two-stage empirical-priors – Male	Fixed	1.58 (1.22, 2.04)	1.14 (0.73, 1.79)	1.38 (0.83, 2.32)	0.056	0.16	0.011	0.028
HMR IPD-AgD NMA – CD4	Fixed	1.34 (0.96, 1.88)	0.94 (0.57, 1.58)	1.42 (0.87, 2.31)	0.226	0.321	0.131	0.148
HMR IPD-AgD NMA – HIV RNA	Fixed	2.03 (0.92, 3.96)	1.36 (0.67, 2.57)	1.48 (0.89, 2.46)	0.16	0.221	0.120	0.170
HMR IPD-AgD NMA – Male	Fixed	2.20 (1.25, 4.02)	1.48 (0.81, 2.80)	1.48 (0.88, 2.48)	0.258	0.309	0.036	0.050

AgD Aggregate data, IPD Individual patient data, NMA Network meta-analysis, EFV Efavirenz, DTG Dolutegravir, EFV₄₀₀ Low-dose efavirenz, OR Odds ratio, CrI Credible interval. Note that DTG vs EFV is estimated through a mixed treatment comparison, EFV₄₀₀ vs EFV by direct comparison and DTG vs EFV₄₀₀ by an indirect comparison

Back to article page

ISSN: 1471-2288

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Medical Research Methodology

Contact us